Nectar Lifesciences Limited (NSE:NECLIFE)

Market Cap	2.35B -53.2%
Revenue (ttm)	92.91M -99.4%
Net Income	-2.93B
EPS	-13.40
Shares Out	194.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,049
Open	12.48
Previous Close	12.45
Day's Range	12.01 - 12.49
52-Week Range	9.30 - 27.77
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	May 30, 2026

About Nectar Lifesciences

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufa...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,786
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NECLIFE

Financial Performance

In fiscal year 2026, Nectar Lifesciences's revenue was 92.91 million, a decrease of -99.44% compared to the previous year's 16.70 billion. Losses were -2.93 billion, 157.6% more than in 2025.